Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome

Cristina L Ronchi, Silviu Sbiera1, Barbara Altieri, Sonja Steinhauser, Vanessa Wild2,3, Michaela Bekteshi, Matthias Kroiss3, Martin Fassnacht and Bruno Allolio

Endocrine and Diabetes Unit, Department of Internal Medicine I, University Hospital, University of Wuerzburg, Oberrdorferbacher-Strasse 6, 97080 Wuerzburg, Germany
1Central Laboratory, University Hospital of Wuerzburg, Wuerzburg, Germany
2Institute of Pathology, University of Wuerzburg, Wuerzburg, Germany
3Comprehensive Cancer Center Mainfranken, Wuerzburg, Germany

Correspondence should be addressed to C L Ronchi
Email Ronchi_C@ukw.de

Abstract

Previous SNP array analyses have revealed genomic alterations of the Notch pathway as being the most frequent abnormality in adrenocortical tumors (ACTs). The aim of the present study was to evaluate the expression of components of Notch signaling in ACTs and to correlate them with clinical outcome. The mRNA expression of JAG1, NOTCH1, and selected target genes of NOTCH1 (HES1, HES5, and HEY2) was evaluated in 80 fresh frozen samples (28 normal adrenal glands (NAGs), 24 adenomas (ACAs), and 28 carcinomas (ACCs)) by quantitative RT-PCR. Immunohistochemistry was performed in 221 tissues on paraffin slides (16 NAGs, 27 ACAs, and 178 ACCs) for JAG1, activated NOTCH1 (aNOTCH1), and HEY2. An independent ACC validation cohort (n = 77) was then also investigated. HEY2 mRNA expression was higher in ACCs than it was in ACAs (P < 0.05). The protein expression of all of the factors was high (H-score 2–3) in a larger proportion of ACCs as compared to ACAs and NAGs (JAG1 in 27, 15, and 10%; aNOTCH1 in 13, 8, and 0%; HEY2 in 66, 61, and 33% respectively, all P < 0.001). High JAG1 expression was associated with earlier tumor stages and lower numbers of metastases in ACCs (both P = 0.08) and favorably impacted overall and progression-free survival (PFS) (131 vs 30 months, hazard ratio (HR) 0.45, and 37 vs 9 months, HR 0.51, both P < 0.005). This impact on overall survival (OS) was confirmed in the validation cohort. No such association was observed for aNOTCH1 or HEY2. In conclusion, different components of the Notch1 signaling pathway are overexpressed in ACCs, which suggests a role for the pathway in malignant transformation. However, JAG1 is overexpressed in a subgroup of ACCs with a better clinical outcome.

Key Words
- adrenocortical tumors
- Notch1 pathway
- JAG1
- Wnt/β-catenin

Introduction

The pathogenesis of both benign adrenocortical adenomas (ACAs) and carcinomas (ACCs) remains incompletely understood (Fassnacht et al. 2013, Else et al. 2014) despite major recent advances (Assie et al. 2014). In a previous study that employed SNP array profiling in adrenocortical tumors (ACTs), we identified the Notch1 signaling pathway as being the most frequently altered pathway in both ACAs and ACCs, followed by alterations...
in Wnt/β-catenin signaling (Ronchi et al. 2013). This observation suggests a major role of Notch signaling in adrenocortical tumorigenesis.

The Notch signaling pathway regulates cell-fate decisions throughout embryonic development and adult life by controlling neurogenesis, angiogenesis, apoptosis, cell cycle, proliferation, and differentiation (Capaccione & Pine 2013). Notch is a transmembrane receptor with an extracellular domain that possesses epidermal growth factor repeats and an intracellular domain that contains a nuclear localization sequence (NICD), an RBP-Jκ-associated module (RAM) domain, a C-terminal PEST region, and seven ankyrin repeats. Up until now, four receptors (NOTCH1, NOTCH2, NOTCH3, and NOTCH4) and six ligands (JAG1, JAG2, DLL1, DLL3, DLL4, and DLK1) have been identified. After the binding of a ligand to the respective receptor, γ-secretase complex mediates the cleavage of the transmembrane domain of the Notch receptor to release the NICD, which then translocates into the nucleus and activates the transcription of several target genes, including the hairy enhancer of split (HES) family, the HES-related (HEY) family, and many others involved in apoptosis (NFκ2, CDKN1A, BIRC5/surviving, BCL2), cell cycle or proliferation (CCND1, DTX1, p21/WAF1, CDKN1A-B, IGFR), transcription (MYC, GATA3), or with unknown function (NOTCH3, PTCRA) (Supplementary Figure S1, see section on supplementary data given at the end of this article) (Ranganathan et al. 2011, Chillakuri et al. 2012).

Dysregulation of the Notch signaling pathway has been implicated in several human cancers. For instance, the translocation t(7;9)(q34;q34.3) or mutations in the NOTCH1 gene (including PEST truncating mutations), which lead to Notch-ligand independent activation or to impaired degradation of activated Notch, have been shown to play a role in T-cell acute lymphoblastic leukemia (Weng et al. 2004, Jundt et al. 2008, Ferrando 2010, Paganin & Ferrando 2011). In solid tumors, both oncogenic actions or a tumor suppressor role of the Notch signaling pathway and its components have been reported, depending on the cell type and context (Supplementary Table S1, see section on supplementary data given at the end of this article) (Radtke & Raj 2003, Balint et al. 2005, Wang et al. 2006, Westhoff et al. 2009, Lobry et al. 2011, Mazur et al. 2012, Rizzo et al. 2013, Carvalho et al. 2014, Du et al. 2014). In most cases, activated Notch signaling is associated with more aggressive behavior and poorer prognosis (Capaccione & Pine 2013). However, in some malignancies, NOTCH1 activation may also induce cell growth arrest (Wang et al. 2007).

Recent data have suggested that Notch works as a hub that enables cross-talk among different oncogenic pathways, such as the Wnt/β-catenin signaling, the Sonic hedgehog (Shh), and the AKT/Pi3K pathways (Supplementary Figure S1, see section on supplementary data given at the end of this article). In particular, the link between Notch and Wnt/β-catenin signaling has been investigated in human development (Balint et al. 2005, Crosnier et al. 2006, Yamamizu et al. 2010, Peignon et al. 2011, Ravindran & Devaraj 2012, Gopalakrishnan et al. 2014), and either additive or opposing effects have been reported, depending on the respective tissue and interfering factors (Kwon et al. 2011, Kim et al. 2012). Interestingly, Notch pathway activation has also been related, either alone or together, to Wnt/β-catenin activation and p53 deletion, to the epithelial–mesenchymal transition that is involved in the initiation of metastasis (Wang et al. 2009a, Espinoza & Miele 2013, Chanrion et al. 2014), and to resistance to treatment (Wang et al. 2009b, Yao & Qian 2010, Ma et al. 2013, Yoon et al. 2014).

Because of its oncogenic role in many cancers, inhibitors of the Notch pathway have been developed either to act at the level of γ-secretase or to bind to Notch ligands or receptors, thereby inhibiting Notch activation and suppressing tumor cell growth (Supplementary Figure S1, see section on supplementary data given at the end of this article) (Groth & Fortini 2012, Capaccione & Pine 2013, Espinoza & Miele 2013, Gordon & Aster 2014, Previs et al. 2014). Several clinical trials with these compounds alone or in combination are currently ongoing or have been recently completed (ClinicalTrials.gov) (Richter et al. 2014, Lee et al. 2015, LoConte et al. 2015, Messersmith et al. 2015). Moreover, inhibiting Notch signaling (i.e., by pretreatment) has been shown to sensitize tumors to platinum compounds or other cytotoxic drugs, such as gemcitabine (Meng et al. 2009, Wang et al. 2010, McAuliffe et al. 2012). Finally, because the Notch ligand JAG1 is overexpressed in many cancers and plays an important role in tumor biology (Steg et al. 2011), targeting JAG1 directly may represent a promising therapeutic tool (Dai et al. 2014, Li et al. 2014).

Adrenal gland morphology and functioning are deeply interconnected, and signaling pathways, such as the Wnt/β-catenin, Shh, and Notch pathways, are required to preserve the integrity of their functioning (Gallo-Payet & Battista 2014). In particular, constitutive activation of the Wnt/β-catenin signaling pathway has been demonstrated to be an early step in adrenocortical tumorigenesis (Tissier et al. 2005, El Wakil & Lalli 2011, Gaujoux et al. 2011), but so far only limited data are available on the
involvement of Notch signaling. However, recurrent copy number gains in the JAG1 (frequency > 50%) or JAG2 gene (frequency > 40%) have been found in ACCs, which suggests a role for these genes in malignant transformation (Ronchi et al. 2013). Furthermore, Simon et al. (2012) demonstrated that the JAG1 gene is overexpressed in ACCs (as compared to normal adrenal glands (NAGs) and ACAs) and that JAG1 up-regulation in Y1 mouse cells is able to enhance cell proliferation and aggressiveness through the activation of Notch signaling in adjacent cells.

The major aim of the present study was therefore to more comprehensively investigate the components of the Notch pathway and their relation to Wnt/β-catenin signaling in NAGs and in a large series of ACTs in order to characterize their potential role in adrenocortical tumorigenesis. Furthermore, we also investigated the relationship between the expression of Notch-related factors and clinical outcome in patients with ACC.

Materials and methods
Tissue samples, patients, and clinical annotations
Eighty fresh frozen adrenal tissues (28 NAGs, 24 ACAs, and 28 ACCs) were used for the evaluation of mRNA levels of several components of the Notch and Wnt/β-catenin pathways.

A series of 236 tissue samples on paraffin slides comprising 16 NAGs (including seven adrenal hyperplasias), 27 ACAs, 178 ACCs, and 15 other tissues serving as controls (including pancreas, colon, prostate, and ovarian cancer) was evaluated by immunohistochemistry. Among the ACC samples, 135 were obtained from surgery of the primary tumor, 26 from local recurrences, and 17 from distant metastases. In that series, 16 of the ACCs had been also investigated as part of a previous SNP array analysis and were used for the comparison between CN alterations and protein expression (Ronchi et al. 2013).

Clinical parameters, such as sex, age at diagnosis, date of surgery, tumor size, results of hormone analysis, and, in the case of ACC, tumor stage according to the European Network for the Study of Adrenal Tumors (ENSAT) classification (Fassnacht et al. 2009), Weiss score, Ki67 proliferation index, presence and number of distant metastases, and detailed follow-up information were collected through the German ACC and ENSAT registries (www.ensat.org/registry). Malignancy and hormonal hypersecretion were defined according to established clinical, biochemical, and morphological criteria (Nieman et al. 2008). The baseline patient and tumor characteristics of both series are given in Table 1. Concerning treatment, 26 ACC patients underwent follow-up only, 34 received mitotane monotherapy (adjuvant or palliative), and 62 underwent chemotherapy with different drug combinations, including platinum compound-based protocols, streptozotocin, gemcitabine plus capcitabine, and others. Thirteen ACC patients were lost to follow-up (unknown treatment).

An independent validation cohort of 77 ACCs (63 obtained from surgery of the primary tumor, six from local recurrences, and eight from distant metastases) was also investigated in a second step by immunohistochemistry to confirm the key results of the first series.

The present study was approved by the ethics committee of the University of Wuerzburg (nos 93/02 and 88/11), and written informed consent was obtained from all of the patients.

NOTCH1 mutation analysis
A total of 46 fresh frozen ACTs (21 ACAs and 25 ACCs) were investigated for the presence of the somatic mutation in exon 34.1 of the NOTCH1 gene, which disrupts the PEST region (c.7544_7545delCT) and leads to constitutive activation. Total tumor DNA was extracted, and mutation analysis was performed by direct Sanger sequencing analysis of PCR products obtained using primer sequences and PCR conditions as previously published (Fabbri et al. 2011, Rossi et al. 2012).

Gene expression analysis
mRNA expression in fresh frozen tissue was investigated by real-time quantitative RT-PCR (qRT-PCR). Among the Notch-related factors, we choose the Notch ligand JAG1 because of previous observations in ACTs as well as the most well-known Notch-specific target genes of the HES/HEY family (HES1, HESS, and HEY2) (Ranganathan et al. 2011, Chillakuri et al. 2012). For the Wnt/β-catenin/TCF/LEF1 axis, we selected the well-characterized target gene LEFI. In brief, RNA was isolated from fresh frozen tissue samples with the RNeasy Lipid Tissue MiniKit (Qiagen) and RT with the QuantiTect Reverse Transcription Kit (Qiagen). Predesigned Taqman (Applied Biosystems, Darmstadt, Germany) gene expression assays for JAG1 (Hs01070032_m1), NOTCH1 (Hs01062014_m1), CTNNB1 (Hs00355049_m1), HES1 (Hs00172878_m1), HESS (Hs01387463_g1), HEY2 (Hs00232622_m1), and LEFI (Hs01547250_m1) were purchased from Applied Biosystems. Endogenously expressed β-actin (Hs9999903_m1)
was used for normalization. Forty nanograms cDNA was used for each PCR reaction, and each sample was performed in duplicate. Transcript levels were determined with the TaqMan Gene Expression Master Mix (Applied Biosystems), the CFX96 real-time thermocycler (Bio-Rad), and Bio-Rad CFX Manager 2.0 Software. Cycling conditions were 3 min at 95 °C followed by 50 cycles of 30 s at 95 °C, 30 s at 60 °C, and 30 s at 72 °C. Using the ΔCT method (Pfaffl 2001), the gene expression levels were normalized to those of β-actin, as previously described (Ronchi et al. 2012).

Immunohistochemistry

According to previous observations and to mRNA expression results, we selected for immunohistochemistry the Notch ligand JAG1, the activated NOTCH1 (aNOTCH1), and the specific Notch target gene HEY2.

### Table 1  Clinical and histopathological characteristics

<table>
<thead>
<tr>
<th></th>
<th>Normal adrenal</th>
<th>Adenoma</th>
<th>Carcinoma</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cohort for mRNA analysis by quantitative RT-PCR</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>28</td>
<td>24</td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>Age (years; median (range))</td>
<td>–</td>
<td>50.5 (25–62)</td>
<td>50 (24–78)</td>
<td>NS</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>–</td>
<td>9/15</td>
<td>14/14</td>
<td>NS</td>
</tr>
<tr>
<td>Tumor size (cm; median (range))</td>
<td>–</td>
<td>3.2 (0.9–8.5)</td>
<td>8 (2.5–24)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Hormone secretion (no. available)</td>
<td>–</td>
<td>24</td>
<td>28</td>
<td>NS</td>
</tr>
<tr>
<td>Aldosterone-producing</td>
<td>–</td>
<td>6</td>
<td>1</td>
<td>NS</td>
</tr>
<tr>
<td>Cortisol-producing</td>
<td>–</td>
<td>11</td>
<td>12</td>
<td>NS</td>
</tr>
<tr>
<td>Androgen-producing</td>
<td>–</td>
<td>0</td>
<td>3</td>
<td>NS</td>
</tr>
<tr>
<td>Inactive</td>
<td>–</td>
<td>7</td>
<td>12</td>
<td>NS</td>
</tr>
<tr>
<td>Primary tumors (no.)</td>
<td>–</td>
<td>–</td>
<td>19</td>
<td>–</td>
</tr>
<tr>
<td>Local recurrence (no.)</td>
<td>–</td>
<td>–</td>
<td>4</td>
<td>–</td>
</tr>
<tr>
<td>Metastases (no.)</td>
<td>–</td>
<td>–</td>
<td>3</td>
<td>–</td>
</tr>
<tr>
<td>ENSAT tumor stage</td>
<td>–</td>
<td>–</td>
<td>13/10/4</td>
<td>–</td>
</tr>
<tr>
<td>ENSAT 1–2/3/4 (no.)</td>
<td>–</td>
<td>–</td>
<td>15</td>
<td>NS</td>
</tr>
<tr>
<td>Proliferation index (Ki67) (%; mean ± s.d.)</td>
<td>–</td>
<td>–</td>
<td>17 ± 10.5</td>
<td>–</td>
</tr>
<tr>
<td>Weiss score (mean ± s.d.)</td>
<td>–</td>
<td>–</td>
<td>6 ± 2</td>
<td>–</td>
</tr>
<tr>
<td><strong>Cohort for protein analysis by immunohistochemistry</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>16</td>
<td>27</td>
<td>178</td>
<td></td>
</tr>
<tr>
<td>Age (years; median (range))</td>
<td>64 (27–79)</td>
<td>48 (31–76)</td>
<td>47 (18–77)</td>
<td>NS</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>–</td>
<td>11/17</td>
<td>56/99</td>
<td>NS</td>
</tr>
<tr>
<td>Tumor size (cm; median (range))</td>
<td>–</td>
<td>2.8 (1–6.5)</td>
<td>11 (3–30)</td>
<td>NS</td>
</tr>
<tr>
<td>Hormone secretion (no. available)</td>
<td>–</td>
<td>28</td>
<td>102</td>
<td>NS</td>
</tr>
<tr>
<td>Androgen-producing</td>
<td>–</td>
<td>0</td>
<td>14</td>
<td>NS</td>
</tr>
<tr>
<td>Aldosterone-producing</td>
<td>–</td>
<td>6</td>
<td>5</td>
<td>NS</td>
</tr>
<tr>
<td>Cortisol-producing</td>
<td>–</td>
<td>15</td>
<td>28</td>
<td>NS</td>
</tr>
<tr>
<td>Mixed</td>
<td>–</td>
<td>0</td>
<td>36</td>
<td>NS</td>
</tr>
<tr>
<td>Inactive</td>
<td>–</td>
<td>7</td>
<td>19</td>
<td>NS</td>
</tr>
<tr>
<td>Primary tumors (no.)</td>
<td>–</td>
<td>–</td>
<td>135</td>
<td>–</td>
</tr>
<tr>
<td>Local recurrence (no.)</td>
<td>–</td>
<td>–</td>
<td>26</td>
<td>–</td>
</tr>
<tr>
<td>Metastases (no.)</td>
<td>–</td>
<td>–</td>
<td>17</td>
<td>–</td>
</tr>
<tr>
<td>ENSAT tumor stage</td>
<td>–</td>
<td>–</td>
<td>63/41/37</td>
<td>–</td>
</tr>
<tr>
<td>ENSAT 1–2/3/4 (no.)</td>
<td>–</td>
<td>–</td>
<td>10 (1–60)</td>
<td>–</td>
</tr>
<tr>
<td>Proliferation index (Ki67) (%; median (range))</td>
<td>–</td>
<td>–</td>
<td>5 (2–9)</td>
<td>–</td>
</tr>
<tr>
<td>Weiss score (median (range))</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>JAG1 protein expression (%)</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>Absent (H-score 0–0.5)</td>
<td>40</td>
<td>46</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>Low (H-score 1)</td>
<td>50</td>
<td>38</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td>High (H-score 2–3)</td>
<td>10</td>
<td>15</td>
<td>27</td>
<td></td>
</tr>
<tr>
<td>NOTCH1 protein expression (%)</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>Absent (H-score 0–0.5)</td>
<td>80</td>
<td>48</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>Low (H-score 1)</td>
<td>20</td>
<td>44</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>High (H-score 2–3)</td>
<td>0</td>
<td>8</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>HEY2 protein expression (%)</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>Absent (H-score 0–0.5)</td>
<td>27</td>
<td>14</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Low (H-score 1)</td>
<td>40</td>
<td>24</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>High (H-score 2–3)</td>
<td>33</td>
<td>61</td>
<td>66</td>
<td></td>
</tr>
</tbody>
</table>

NS, not significant.
A total of 263 paraffin-embedded specimens, including 76 standard full slides and 187 samples assembled into three tissue microarrays (TMAs) were investigated by immunohistochemistry. TMA samples were included in the analysis only if two or more evaluable cores per patient were available after the staining procedure. Thus, the final series included 236 tissue samples (16 NAGs, 27 ACAs, 178 ACCs, and 15 positive controls; see ‘Tissue samples’ above). The validation cohort consisted of 77 ACCs distributed on three new TMAs.

**Immunostaining for JAG1, activated NOTCH1, and HEY2** TMA and full sections were deparaffinized, and immunohistochemical detection was performed with an indirect immunoperoxidase technique after high temperature antigen retrieval in 10 mM citric acid monohydrate buffer (pH 6.5) in a pressure cooker for 13 min. Blocking of unspecific protein–antibody interactions was performed with 20% human AB serum in PBS for 1 h at room temperature. Primary antibody for JAG1 was a monoclonal anti-rabbit antibody (EPR4290, Lifespan Bioscience, Seattle, WA, USA) at a dilution of 1:300 at 4 °C. Primary antibody for aNOTCH1 was a polyclonal anti-rabbit antibody against the cleaved NICD (ab 8925, epitope: VLLSRKRRRQHGQC, Abcam, Cambridge, UK) at a dilution of 1:200 at 4 °C. Primary antibody for HEY2 was a polyclonal anti-rabbit antibody (HPA030205, Sigma–Aldrich) at a dilution of 1:100 at 4 °C, together with N-Universal Negative Control Anti-Rabbit (Dako, Glostrup, Denmark). Signal amplification was achieved by En-Vision System Labeled Polymer-HRP Anti-Rabbit (Dako) for 40 min and was then developed for 10 min with DAB Substrate Kit (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer’s instructions. Nuclei were counterstained with Mayer’s hematoxilin for 2 min. For positive controls, sections with colon cancer, pancreas cancer, and prostate cancer were chosen, whereas cells were counterstained with Mayer’s hematoxilin for 2 min. Nuclei were counterstained with Mayer’s hematoxilin for 2 min. Nuclei were counterstained with Mayer’s hematoxilin for 2 min. Nuclei were counterstained with Mayer’s hematoxilin for 2 min.

All of the slides were analyzed independently by two investigators blinded to clinical information (CLR and SSt).

Both nuclear and cytoplasmic staining was evaluated according to the expected localization (cytoplasmatic and membranous for JAG1, nuclear for aNOTCH1 and HEY2), and staining intensity was graded as negative (0), low (1), medium (2), or strong (3). The percentage of positive tumor cells was calculated for each specimen and scored as 0 if 0% were positive, as 0.1 if 1–9% were positive, as 0.5 if 10–49% were positive, and as 1 if 50% or more were positive. A semi-quantitative H-score was then calculated by multiplying the staining intensity grading score with the proportion score as described previously (Ronchi et al. 2009). When discrepancies were observed, results were jointly assessed by both investigators and the final score was formed by consensus. Inter-observer agreement was strong, with a Pearson’s correlation coefficient of 0.83 (95% CI 0.78–0.87) for JAG1 and 0.67 (95% CI 0.58–0.75) for aNOTCH1.

**Immunostaining for β-catenin** Immunohistochemistry for β-catenin had been previously performed on the present TMAs, and the results have already been published elsewhere (Gaujoux et al. 2011, Ronchi et al. 2012). In brief, primary antibody was provided by BD Bioscience (1:400; San Jose, CA, USA), and the nuclear staining (representative of β-catenin pathway activation) was assessed as previously described (Gaujoux et al. 2011). A total of 59 cases among those assembled in the TMAs with fewer than two evaluable cores were excluded from the final series (seven ACAs, 50 ACCs, and two NAs), which left a final series of 144 samples.

**Statistical analysis** Fisher’s exact test or \( \chi^2 \) test was used to investigate dichotomous variables, whereas two-sided \( t \)-test (or non-parametric test) was used to test continuous variables. Non-parametric Kruskal–Wallis test, followed by Bonferroni post hoc test, was used for comparison among several groups for non-normal distributed variables. Correlations and 95% CIs between different parameters were evaluated by linear regression analysis. OS was defined as the time

![Figure 1](image-url)
from the date of primary surgery to specific death or last follow-up, whereas PFS was defined as the time from the date of primary tumor resection to the first radiological evidence of any kind of disease progression or relapse or death. Time to progression (TTP) during therapy was defined as the time from the date of first administration to the first radiological evidence of any kind of disease progression or relapse or death. All survival curves were obtained by Kaplan–Meier estimates, and the differences between survival curves were assessed by the log-rank (Mantel–Cox) test. For the calculation of hazard ratios (HRs), two ACC groups with low or high protein expression were considered (JAG1 high-expression H-score ≥ 1; HEY2 H-score ≥ 2). A multivariate regression analysis was performed by Cox proportional hazard regression model to identify those factors that might independently influence survival. Statistical analyses were made using GraphPad Prism version 5.0 (La Jolla, CA, USA) and SPSS Software PASW Version 21.0 (SPSS, Inc., Chicago, IL, USA). P values of <0.05 were considered statistically significant.

Results

**NOTCH1 mutation analysis**

None of the 46 investigated ACTs (21 ACAs, 25 ACCs) had the known activating somatic mutation of the PEST region of the NOTCH1 gene (c.7544_7545delCT).

**mRNA expression of JAG1 and other Notch-related factors**

Considering all of the 80 samples together (NAGs, ACAs, and ACCs), the mRNA expression of HES1 and HEY2 was positively correlated with NOTCH1 (R=0.46, P<0.005,

![Figure 2](image-url)

**Figure 2**

Examples of immunostaining of activated NOTCH1 (aNOTCH1) (A), JAG1 (B), and HEY2 (C) in a normal adrenal gland (NAG) and an adrenocortical carcinoma (ACC) (H-score 2).
and $R=0.22$, $P=0.077$, respectively), JAG1 was positively correlated with both HES1 and HEY2 ($R=0.28$, $P=0.05$, and $R=0.24$, $P=0.05$, respectively), and LEF1 was positively correlated with CTNNB1 ($R=0.72$, $P<0.005$), which indicates that the up-regulation of upstream signaling results in enhanced target gene expression. HEY2 mRNA expression was significantly higher in ACCs than in ACAs (0.0084 ± 0.0094 vs 0.0042 ± 0.0060, $P<0.05$), whereas JAG1 and HES1 showed only a trend to higher levels in ACCs (both $P=0.13$; Fig. 1). The other evaluated factors (NOTCH1, HES5, CTNNB1, and LEF1) were similar in the three groups (NAGs, ACAs, and ACCs).

Concerning the relationship with clinical parameters, we observed a positive correlation between tumor size and mRNA levels of CTNNB1 ($R=0.41$, $P<0.005$), HES1 ($R=0.37$, $P<0.01$), and HEY2 ($R=0.37$, $P<0.05$). However, no other significant correlations were observed between the mRNA expression of the investigated markers and clinical or histopathological parameters (ENSAT tumor stage, Weiss score, Ki67, number of distant metastases, and hormone secretion status).

### Protein expression of JAG1, aNOTCH1, HEY2, and β-catenin

Representative examples of JAG1, aNOTCH1, and HEY2 staining in adrenal tissue are shown in Fig. 2. Both aNOTCH1 and JAG1 staining were relatively inhomogeneous, with the percentage of positive cells ranging from 10 to 85% and from 15 to 90% respectively. In contrast, HEY2 staining had a homogeneous tissue distribution in the entire series (>50% positive cells in more than 90% of samples).

All three of the evaluated components of the Notch1 signaling pathway were more strongly expressed in ACCs than they were in the other subgroups. In particular, JAG1 protein was highly expressed (H-score 2–3) in 10% of NAGs, 15% of ACAs, and 27% of ACCs ($P<0.0005$ by $\chi^2$ test), and nuclear aNOTCH1 protein was highly expressed in 0% of NAGs, 8% of ACAs, and 13% of ACCs ($P<0.005$). HEY2 protein, which exhibited stronger staining intensity, was highly expressed (H-score 2–3) in 33% of NAGs, 61% of ACAs, and 66% of ACCs ($P<0.005$; Table 1). Figure 3 shows the comparison in terms of H-score values among the three groups (NAGs, ACAs, and ACCs) for JAG1, aNOTCH1, and HEY2. On the other hand, nuclear β-catenin expression was detected in a larger proportion of NAGs and ACAs than ACCs ($P<0.0001$).

Of note, JAG1 expression significantly correlated with both aNOTCH1 and HEY2 in NAGs and ACAs ($P<0.001$ and $P<0.05$ by $\chi^2$ test respectively) but not in ACCs (Supplementary Figure S2A, see section on supplementary data given at the end of this article), which suggests a conserved activation of the canonical Notch1 pathway in benign tumors but deregulated signaling in malignant tumors. Furthermore, nuclear β-catenin expression positively correlated with JAG1 only in ACAs ($P<0.005$ by $\chi^2$ test) and with HEY2 in both ACAs and ACCs (both $P<0.005$; Supplementary Figure S2B).

In the ACC group, no significant difference was observed among tumors that derived from first surgery ($n=140$), from local recurrence ($n=26$), or from metastasis ($n=14$) for JAG1, aNOTCH1, and HEY2 protein expression. Among primary ACCs, JAG1 expression negatively correlated with tumor size ($R=0.18$, $P=0.056$) and showed a trend toward higher expression in patients with early ENSAT tumor stages (1–3, $P=0.08$) and in those with early ENSAT tumor stages (1–3, $P=0.08$).
with a lower number of distant metastases ($P=0.08$). In contrast, HEY2 levels were higher in patients with metastatic tumors ($P<0.01$).

JAG1 expression was higher in the nine ACCs that were affected by copy number gains in the previous SNP array analysis (22% of cases with H-score <1; 44% with H-score 1; and 33% with H-score 2–3) as compared to the seven ACCs with normal copy numbers (43% of cases with H-score <1; 57% with H-score 1, $P<0.005$; Supplementary Figure S3, see section on supplementary data given at the end of this article).

**Relationship between protein expression of JAG1, aNOTCH1, and HEY2 and clinical outcome**

Among ACCs, patients with higher JAG1 protein expression levels (H-score ≥1) had a significantly longer OS (median 131 vs 30 months, $P<0.005$, HR 0.45, 95% CI 0.32–0.77) and PFS (median 37 vs 9 months, $P<0.005$, HR 0.51, 95% CI 0.35–0.78; Table 2). The favorable impact of high JAG1 expression on OS remained significant after adjustment for ENSAT tumor stage ($P<0.01$) and nuclear β-catenin expression ($P<0.01$). Interestingly, ACCs with negative nuclear β-catenin expression ($n=62$) had an impressively longer OS in cases of concomitant high JAG1 ($n=37$, median 126 months) than that in cases of concomitant low JAG1 ($n=25$, median 21 months, $P<0.01$, HR 0.34, 95% CI 0.09–0.64; Fig. 4A).

Furthermore, the positive influence of high JAG1 expression on clinical outcome was particularly evident in the subgroup of patients who did not receive any pharmacological treatment ($n=26$, $P<0.05$, HR 0.42, 95% CI 0.19–1.27) or cytotoxic drugs ($n=62$, $P=0.64$, HR 0.87, 95% CI 0.45–1.6).

In contrast, high HEY2 protein expression (H-score 2–3) was associated with a negative prognostic role in terms of OS (median 35 vs 86 months, $P=0.10$, HR 1.47, 95% CI 0.94–2.26) and PFS (median 9 vs 31 months, $P=0.13$, HR 1.34, 95% CI 0.91–2.02; Table 2). The combined analysis

---

**Table 2** Relationship between activated NOTCH1 (aNOTCH1), JAG1, and HEY2 protein expression and clinical outcome of patients with adrenocortical carcinoma* (univariate analysis)

<table>
<thead>
<tr>
<th></th>
<th>Median survival (months)</th>
<th>HR (95% CI)</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Overall survival</td>
<td>Free progression survival</td>
</tr>
<tr>
<td>aNOTCH1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low (H-score &lt;1)</td>
<td>82</td>
<td>35</td>
<td>0.80 (0.53–1.21)</td>
</tr>
<tr>
<td>High</td>
<td>57</td>
<td>45</td>
<td>0.45 (0.32–0.77)</td>
</tr>
<tr>
<td>JAG1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low (H-score 0–1)</td>
<td>101</td>
<td>30</td>
<td>1.47 (0.94–2.26)</td>
</tr>
<tr>
<td>High (H-score 2–3)</td>
<td>36</td>
<td>131</td>
<td>1.71 (1.05–2.99)</td>
</tr>
<tr>
<td>HEY2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>44</td>
<td>86</td>
<td>0.86 (0.58–1.23)</td>
</tr>
<tr>
<td>High</td>
<td>83</td>
<td>35</td>
<td>0.51 (0.35–0.78)</td>
</tr>
<tr>
<td>Nuclear β-catenin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>53</td>
<td>89</td>
<td>1.37 (0.92–2.07)</td>
</tr>
<tr>
<td>High</td>
<td>42</td>
<td>38</td>
<td>1.8 (1.17–3.12)</td>
</tr>
</tbody>
</table>

*HR, hazard ratio; 95% CI.

*Only ACC samples with complete available clinical data (total $n=137$).
with nuclear β-catenin expression showed a longer OS in the subgroup of patients with negative HEY2 and negative nuclear β-catenin (n = 21, P = 0.058; Fig. 4B).

Nuclear aNOTCH1 protein expression had no significant impact on OS or PFS (data not shown).

A multivariate regression analysis (by Cox regression test), including the expression of JAG1, aNOTCH1, HEY2, β-catenin, ENSAT tumor stage, and proliferation index Ki67, revealed an independent impact on OS only for JAG1 (P = 0.07, HR 0.46), tumor stage (P < 0.05, HR 2.79), and Ki67 (P < 0.005, HR 3.81).

**Validation ACC cohort**

We also evaluated JAG1 and HEY2 protein expression in the independent cohort of 77 ACCs in order to validate the results of the first series. HEY2 was similarly expressed in the first series and in the validation series of ACCs, whereas JAG1 was more highly expressed in the validation series (P < 0.05 vs first ACC series, P < 0.0005 vs ACAs; Supplementary Figure S4, see section on supplementary data given at the end of this article).

Moreover, despite the lower number of patients, the favorable impact of JAG1 protein levels on OS remained significant in the validation cohort of ACC patients (median 108 vs 50 months, P < 0.05, HR 0.47, 95% CI 0.24–0.94). Similarly to what we observed in the first series, high HEY2 expression levels were associated with a trend toward a worse prognosis (median OS 50 vs 100 months, P = 0.13, HR 1.68, 95% CI 0.86–3.37). A graphical representation of the survival analysis for JAG1 in the first series and in the validation ACC series is shown in the Fig. 5.

**Discussion**

In a previous investigation that employed SNP array analysis, Notch signaling emerged as the most frequently altered pathway in adrenocortical neoplasias (Ronchi et al. 2013). In the present study, we therefore performed a more detailed analysis of components of this complex pathway in adrenal tumors at different levels. We found overexpression of the NOTCH1 ligand JAG1 and the downstream target of NOTCH1 HEY2 in ACCs as compared to NAGs or to benign adrenocortical lesions, at both the mRNA and the protein level. These results were also confirmed by immunohistochemistry in an independent validation cohort of ACCs. Furthermore, activated NOTCH1 protein expression was more frequently detected in malignant ACTs. However, no activating mutations in the PEST region of the NOTCH1 gene (Weng et al. 2004, Jundt et al. 2008, Ferrando 2010, Fabbri et al. 2011, Paganin & Ferrando 2011, Rossi et al. 2012) were detected in ACCs. Of note, although gene expression of Notch1 pathway components correlated significantly in normal adrenals and adenomas, this relationship was lost in ACCs, which indicates dysregulation of Notch1 signaling in malignant tumors. Taken together, these observations confirm the activation of the Notch1 pathway in adrenocortical neoplasias, particularly in ACCs.

Overexpression of the Notch ligand JAG1 was related to a copy number gain of the JAG1 gene in the subset of tumors for which SNP array data were available, which suggests that this mechanism may at least in part underlie the increased expression of JAG1. However, although high expression of JAG1 was more often found in ACCs than in ACAs or NAGs, it was characteristic of a subgroup of ACCs with a more differentiated phenotype and better prognosis. In particular, high JAG1 expression tended to be more frequent in smaller tumors, in early tumor stages,
and in tumors with lower numbers of distant metastasis. Furthermore, it was associated with a better prognosis in terms of both improved PFS and improved OS. The favorable impact of JAG1 expression on general clinical outcome was also confirmed in the smaller validation ACC cohort. Therefore, high JAG1 indicates a less detrimental prognosis in ACCs.

Higher expression of JAG1 in ACCs as compared to ACAs and normal adrenals has already been described by Simon et al. (2012), but no prognostic impact was reported in that study. Instead, the authors showed that JAG1 overexpression in murine Y1 cells led to enhanced cell proliferation and aggressiveness. This discrepancy may be explained at least in part by the specific cellular context of Y1 cells and by species differences.

Intriguingly, the favorable impact of high JAG1 expression on clinical outcome was particularly evident in tumors with negative nuclear β-catenin expression, which supports the well-described importance of the interconnection of the Wnt/β-catenin pathway (Balint et al. 2005, Crosnier et al. 2006, Wang et al. 2009a, Yamamizu et al. 2010, Kwon et al. 2011, Peignon et al. 2011, Kim et al. 2012, Ravindran & Devaraj 2012, Gopalakrishnan et al. 2014).

Unlike JAG1, high HEY2 protein expression was instead a marker of a more aggressive tumor type with an inferior clinical outcome, although the impact on OS was not significant. This discrepancy with the JAG1 findings may reflect the profound dysregulation of the Notch pathway in ACCs and the role of additional influences downstream of Notch. The demonstration of Notch activation and the overexpression of its target genes in patients with advanced ACCs may become therapeutically relevant, considering the potential use of Notch-inhibiting drugs that act downstream of JAG1, such as γ-secretase inhibitors, which are currently under investigation alone and in combination in clinical trials for Notch-dependent solid tumors (Richter et al. 2014, Lee et al. 2015, LoConte et al. 2015, Messersmith et al. 2015), or more innovative compounds, such as receptor-blocking monoclonal antibodies (Supplementary Figure S1, see section on supplementary data given at the end of this article) (Hernandez Tejada et al. 2014).

Although the present investigation is the first attempt to analyze in more detail the Notch pathway in adrenocortical neoplasia, there remain clear limitations. The Notch pathway is highly complex, with four receptors, multiple ligands beyond JAG1, and several direct

Figure 5
Overall survival analysis by Kaplan–Meyer curves in the first series of adrenocortical carcinomas (ACCs, A, C, n = 137) and in the validation series (B and D, n = 77) for JAG1 protein expression (A and B) and HEY2 protein expression (C and D). β-cat, β-catenin.
downstream targets in addition to the best-described Notch–HES/HEY family (Iso et al. 2003) that also participate in other important signaling pathways, such as the Wnt/β-catenin pathway (e.g., MYC, CCND1, and survivin) (Borggreve & Oswald 2009). Moreover, the Notch pathway interacts at different levels with other oncogenic pathways, such as the Wnt/β-catenin signaling, the Shh, and the AKT/P13K pathways (Supplementary Figure S1, see section on supplementary data given at the end of this article). Thus, a complete analysis would require the inclusion of many more components. However, the parameters evaluated in the present study are established key components of this pathway, and they allow important first insights into Notch signaling in adrenal neoplasias.

In summary, the activation of Notch1 signaling is demonstrated in ACCs, which suggests a potential role for Notch1 signaling in malignant adrenocortical transformation. However, JAG1 is overexpressed in a subgroup of ACCs that are characterized by a more differentiated phenotype and a better clinical outcome.

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/ERC-15-0163.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported by a grant from the Wilhelm Sander Foundation (grant number 2012.095.1 to B Allolio). Furthermore, support was also received from the Deutsche Forschungsgemeinschaft DFG (grant numbers KR-43741/1-1 to M Kroiss and FA-466/1-1 to M Fassnacht) and from the IZKF Würzburg (grant number B-281 to M Fassnacht).

Acknowledgements
The authors are grateful to Martina Zink for excellent technical support and to Michaela Haaf for coordinating the German ACC Registry.

References


Li D, Masiero M, Banham AH & Harris AL 2014 The notch ligand JAGGED1 as a target for anti-tumor therapy. Frontiers in Oncology 4 254. (doi:10.3389/fonc.2014.00254)


Received in final form 11 May 2015
Accepted 15 May 2015
Made available online as an Accepted Preprint 15 May 2015